USPTO extends BL-1020 patent rights
The patent will extend coverage period by at least until 2031, which is nine years longer than the granted patent coverage earlier to the company. The patent applications
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
The randomised, double-blind trial will compare progression-free survival in 329 post-ASCT patients receiving Adcetris to those receiving placebo. Patients receive Adcetris every three weeks for up to one